Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy — Case Studies
-
2m 55s
Watch these two brief patient case studies and take a moment to answer a short poll for each one.
Your responses will help shape a practical discussion focused on supporting clinical decision-making in real-world settings.
As part of our expert-led programme, Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy, taking place on 02 July 2025, the Faculty will explore current trends in RAAS inhibitor (RAASi) use, the challenges hyperkalaemia poses to maintaining guideline-directed medical therapy (GDMT), and strategies to optimise treatment while minimising risk.
Through real-world evidence and case-based dialogue, the session aims to enhance clinical competence, encourage reflection on current practices, and support improved outcomes for patients with complex needs.
More from this programme
Part 1
A 74-Year-Old with HF, CKD and T2DM
Prof James Burton (University of Leicester, UK) presents a complex case of a 74-year-old patient with CKD, heart failure, and T2DM on guideline-directed medical therapy (GDMT), who develops hyperkalaemia.
How would you approach treatment in this scenario?
Watch the case and share your perspective by answering the poll.
Part 2
A 68-Year-Old with HF and CKD Managed for Hyperkalaemia in Primary Care
Dr Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK) presents the case of a 68-year-old patient with chronic kidney disease (CKD) and heart failure on sub-maximal guideline-directed medical therapy (GDMT), who develops hyperkalaemia in the community setting.
What would be your next step in managing this patient?
Watch the case and share your approach by answering the poll.
Faculty Biographies
James Burton
Professor of Renal Medicine
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical…
Aaron Wong
Consultant Cardiologist
Dr Aaron Wong is consultant cardiologist and general physician at the Princess of Wales Hospital, Bridgend, Wales, UK and is also an honorary lecturer at the University of Cardiff, UK.
His research interests include heart failure and cardiometabolic disease.